Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

BACKGROUND: The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, we report results on the final efficacy and interim safety analyses of the phase 3 trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Halperin, Scott A, Ye, Lingyun, MacKinnon-Cameron, Donna, Smith, Bruce, Cahn, Pedro E, Ruiz-Palacios, Guillermo M, Ikram, Aamer, Lanas, Fernando, Lourdes Guerrero, M, Muñoz Navarro, Sergio Raúl, Sued, Omar, Lioznov, Dmitry A, Dzutseva, Vitalina, Parveen, Ghazala, Zhu, Fengcai, Leppan, Laura, Langley, Joanne M, Barreto, Luis, Gou, Jinbo, Zhu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700283/
https://www.ncbi.nlm.nih.gov/pubmed/34953526
http://dx.doi.org/10.1016/S0140-6736(21)02753-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700283/
https://www.ncbi.nlm.nih.gov/pubmed/34953526
http://dx.doi.org/10.1016/S0140-6736(21)02753-7

Ejemplares similares